Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

In vivo genome-wide CRISPR screening identifies CITED2 as a driver of prostate cancer bone metastasis

7 Mar 2024

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Genomics and Diagnostics
Share to Multiple Myeloma Research and Treatments
Share to Prostate Cancer Treatment and Research

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 38454137
DOI: 10.1038/s41388-024-02995-5

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

In vivo genome-wide CRISPR screening identifies CITED2 as a driver of prostate cancer bone metastasisPMID 38454137Read ↗

An integrated functional and clinical genomics approach reveals genes driving aggressive metastatic prostate cancerSemantic proximity Read ↗

CRISPR/Cas9 model of prostate cancer identifies Kmt2c deficiency as a metastatic driver by Odam/Cabs1 gene cluster expressionSemantic proximity Read ↗

Genome-wide CRISPR screen identifies PRC2 and KMT2D-COMPASS as regulators of distinct EMT trajectories that contribute differentially to metastasisSemantic proximity Read ↗

CRISPR Screen Contributes to Novel Target Discovery in Prostate CancerSemantic proximity Read ↗

Integrative CRISPR-Cas9 Screening Reveals Lethal Genes Driving Metastasis and Prognosis in Prostate AdenocarcinomaSemantic proximity Read ↗

CRISPR/Cas9 model of prostate cancer identifies Kmt2c deficiency as a metastatic driver by Odam/Cabs1 gene cluster expressionSemantic proximity Read ↗

CRISPR/Cas9 Technology Providing a Therapeutic Landscape of Metastatic Prostate CancerSemantic proximity Read ↗

CRISPR-Cas9 ERβ deletion reveals roles in prostate.Semantic proximity Read ↗

Targeting mRNA-coding genes in prostate cancer using CRISPR/Cas9 technology with a special focus on androgen receptor signalingSemantic proximity Read ↗

FOXA1 knock-out via CRISPR/Cas9 altered Casp-9, Bax, CCND1, CDK4, and fibronectin expressions in LNCaP cells.Semantic proximity Read ↗

Integrative identification of non-coding regulatory regions driving metastatic prostate cancerSemantic proximity Read ↗

CRISPR genome-wide screening identifies PAK1 as a critical driver of ARSI cross-resistance in prostate cancer progressionSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.